NCT07492394 2026-04-02
Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer
Hebei Medical University Fourth Hospital
Phase 2 Recruiting
Clinical Trials
10 trialsNCT02393794 2025-10-06
Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
University of Kansas Medical Center
Phase 1/2 Active not recruiting
NCT03426891 2025-10-06
Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02836548 2025-07-10
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma
The Netherlands Cancer Institute
Phase 1/2 Completed
NCT01460940 2017-11-14
A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT00719875 2017-03-03
HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer
Yale University
Phase 1 Completed
NCT00738751 2015-02-04
Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01090973 2013-12-16
Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00005624 2012-09-25
CI-994 in Treating Patients With Advanced Myeloma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00866762 2011-12-12
A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia
Copenhagen University Hospital at Herlev
Phase 2 Unknown